Innovent Biologics Statistics
Total Valuation
IVBXF has a market cap or net worth of 10.93 billion. The enterprise value is 10.24 billion.
| Market Cap | 10.93B |
| Enterprise Value | 10.24B |
Important Dates
The next estimated earnings date is Friday, August 22, 2025.
| Earnings Date | Aug 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.35% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.44B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.47 |
| PB Ratio | 6.08 |
| P/TBV Ratio | 6.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -789.46 |
| EV / Sales | 7.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.35 |
| Quick Ratio | 2.08 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.17 |
Financial Efficiency
Return on equity (ROE) is -0.74% and return on invested capital (ROIC) is -2.94%.
| Return on Equity (ROE) | -0.74% |
| Return on Assets (ROA) | -2.24% |
| Return on Invested Capital (ROIC) | -2.94% |
| Return on Capital Employed (ROCE) | -4.39% |
| Revenue Per Employee | 228,102 |
| Profits Per Employee | -2,291 |
| Employee Count | 5,659 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 2.69 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +37.36% in the last 52 weeks. The beta is 0.31, so IVBXF's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +37.36% |
| 50-Day Moving Average | 5.31 |
| 200-Day Moving Average | 5.13 |
| Relative Strength Index (RSI) | 59.80 |
| Average Volume (20 Days) | 670 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, IVBXF had revenue of 1.29 billion and -12.96 million in losses. Loss per share was -0.01.
| Revenue | 1.29B |
| Gross Profit | 960.41M |
| Operating Income | -103.56M |
| Pretax Income | -10.77M |
| Net Income | -12.96M |
| EBITDA | -65.80M |
| EBIT | -103.56M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 1.08 billion in cash and 387.86 million in debt, giving a net cash position of 692.24 million.
| Cash & Cash Equivalents | 1.08B |
| Total Debt | 387.86M |
| Net Cash | 692.24M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.80B |
| Book Value Per Share | 1.10 |
| Working Capital | 808.86M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 74.40%, with operating and profit margins of -8.02% and -1.00%.
| Gross Margin | 74.40% |
| Operating Margin | -8.02% |
| Pretax Margin | -0.83% |
| Profit Margin | -1.00% |
| EBITDA Margin | -5.10% |
| EBIT Margin | -8.02% |
| FCF Margin | n/a |
Dividends & Yields
IVBXF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.35% |
| Shareholder Yield | -4.35% |
| Earnings Yield | -0.12% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |